The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
A user with diffuse thinning experienced no hair regrowth with finasteride or Avodart but slowed hair loss with Avodart. They are considering trying Minoxidil and are seeking advice on whether to use foam or liquid, and if combining it with other treatments could be beneficial, excluding micro-needling due to scalp irritation concerns.
User suggests a DIY zix formula for hair loss treatment and shares personal success with it. Another user disagrees, calling zix a "snake oil potion" and advises finding a real treatment instead.
The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.
The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.
The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.
Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.
Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.
Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.
The conversation is about the order of applying hair loss treatments, specifically The Ordinary serum and Zix. The user is unsure which to apply first due to the alcohol content in Zix.
The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
The user experienced side effects from oral finasteride and tried mixing it with liquid minoxidil but faced application issues. They are seeking a 5% minoxidil foam with a maximum of 0.15% topical finasteride concentration.
The user shared progress pictures showing significant hair regrowth after three months using 5% foam minoxidil, 0.3% dutasteride, microneedling, pumpkin seed oil, and rosemary oil. The user reported no side effects and chose topical treatments to avoid them.
Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.
SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.
A user is seeking a UK source for a combined minoxidil and RU58841 solution that doesn't contain scalp-irritating ingredients. They specifically want a product without propylene glycol (PG).
Minoxidil is effective for frontal hair loss, despite packaging suggesting it's for crown thinning. The user has seen results with Minoxidil from a different provider.
Alcohol-free minoxidil options in Europe, particularly from a German pharmacy, are recommended for those with seborrheic dermatitis. Users suggest alternatives like Alopexy and Doppelherz foam, and emphasize avoiding propylene glycol and alcohol to reduce irritation.
The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
Apply minoxidil at least 1-2 hours before bed to ensure it dries and doesn't transfer to the pillow. Foam dries faster than liquid, and using a satin beanie after drying can help prevent transfer.